Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy
about
Targeted therapies in sarcomas: challenging the challengeTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaModeling Alveolar Soft Part Sarcomagenesis in the Mouse: A Role for Lactate in the Tumor MicroenvironmentIdentification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray.Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targetsAlveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies.Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literatureAlveolar soft-part sarcoma in the sacrum: a case report and review of the literature.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionMolecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to knowHypoxia induces TFE3 expression in head and neck squamous cell carcinomaTargeted therapies: the rare cancer paradigm.Alveolar Soft Part Sarcoma-A Histological Surprise in a Male Patient who was Suspected to have Breast Cancer.
P2860
Q21285014-B428F023-0072-40B3-8A37-B64B7D81673DQ26747666-1E2B2403-943E-4BEC-86CB-02DC579FB99EQ30050175-00348323-A048-4E95-B639-C8B59E73C1F8Q33598883-98E49FFC-F97B-49CE-A119-08EB321D703BQ34504946-92AF5ACB-6167-4594-A158-55F4F49DB306Q34638089-CC881A8E-2D18-4CB1-8831-21844580BA91Q34638820-F81BC03B-CDED-446E-BFA9-F430FCC84664Q35007669-9E5E89A1-9F24-4203-91DD-34516665588EQ35767389-6F74920A-D8F9-44BE-9D36-59FAF2A07EDCQ36819466-E4D0DF58-E52F-4509-BBC5-9E2C58FA9B63Q36998335-7186CAFE-9A9E-4FE8-8763-211DDFDCB44EQ37632825-E57EA5DB-4D9E-45E9-A763-FD7FDA6019D3Q40395975-73B1000B-8864-4161-90D6-B8D0CF6DF72D
P2860
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@ast
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@en
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@nl
type
label
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@ast
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@en
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@nl
prefLabel
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@ast
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@en
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@nl
P2093
P2860
P3181
P1476
Therapeutic vulnerability of a ...... SPS) to antiangiogenic therapy
@en
P2093
David S Schrump
David T Vistica
Donna O Butcher
Gary Stone
Luke H Stockwin
Mark Raffeld
Melinda Hollingshead
Robert H Shoemaker
Sandra Burkett
Susan Kenney
P2860
P304
P3181
P356
10.1097/MPH.0B013E3181A6E043
P407
P577
2009-08-01T00:00:00Z